We currently have four portfolio companies each advancing specific assets in various stages of development that address significant unmet needs:
Nuralis Pharmaceuticals is an Oncology specialty portfolio company developing an innovative, first-in-class therapy for the detection of recurrence and the treatment of thyroid cancer.
Sciurus Pharmaceuticals is an Oncology specialty portfolio company developing targeted anti-cancer therapies with better efficacy and improved safety profiles.
Giovel Pharmaceuticals is a Gastroenterology specialty portfolio company developing a novel, first-in-class therapy for functional GI disease with specific focus on Postprandial Distress Syndrome (PDS), an area of high unmet need in Gastroenterology.
Giathera Pharmaceuticals is a Gastroenterology specialty portfolio company initially focused on unmet needs in pediatrics.